- Home
- GH vs ACM Comparison
GH vs ACM Comparison
Compare GH & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | ACM |
|---|---|---|
| Founded | 2011 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 11.4B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GH | ACM |
|---|---|---|
| Price | $85.12 | $88.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 10 |
| Target Price | $117.80 | ★ $132.70 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | 6.74 | ★ 42.71 |
| EPS | N/A | ★ 0.56 |
| Revenue | $982,021,000.00 | ★ $16,139,622,000.00 |
| Revenue This Year | $33.40 | $4.54 |
| Revenue Next Year | $28.55 | $5.71 |
| P/E Ratio | ★ N/A | $161.59 |
| Revenue Growth | ★ 32.88 | 0.21 |
| 52 Week Low | $36.36 | $85.00 |
| 52 Week High | $120.74 | $135.52 |
Technical Indicators
Market Signals| Indicator | GH | ACM |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 38.68 |
| Support Level | $82.26 | $87.56 |
| Resistance Level | $103.16 | $100.41 |
| Average True Range (ATR) | 3.94 | 2.74 |
| MACD | 0.07 | -0.32 |
| Stochastic Oscillator | 20.02 | 8.06 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About ACM AECOM
Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets including water, transportation, and environment. Based in Dallas, Aecom employs 51,000. The company generated $16.1 billion in sales in fiscal 2025.